Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE): Assessment of a Novel DES Platform For Percutaneous Coronary Revascularization in Patients With Ischemic Coronary Disease and NSTEMI Acute Coronary Syndrome

Trial Profile

Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE): Assessment of a Novel DES Platform For Percutaneous Coronary Revascularization in Patients With Ischemic Coronary Disease and NSTEMI Acute Coronary Syndrome

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 28 Nov 2018

At a glance

  • Drugs Anti-CD34 monoclonal antibody/sirolimus (Primary)
  • Indications Coronary artery disease
  • Focus Registrational; Therapeutic Use
  • Acronyms HARMONEE
  • Sponsors OrbusNeich
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 30 Oct 2017 Results presented in an OrbusNeich media release.
    • 30 Oct 2017 According to an OrbusNeich media release, new results were reported in the First Report Investigations session at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top